HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.

AbstractBACKGROUND:
Sclerostin, which is secreted exclusively by osteocytes, is a negative regulator of bone formation. The role of sclerostin in chronic kidney disease-mineral and bone disorder is not well known. In the present study, we examined the relationship between serum sclerostin levels, bone turnover markers, and bone mineral density (BMD) of the radius in maintenance hemodialysis patients.
METHODS:
This was a cross-sectional study that analyzed sclerostin, bone alkaline phosphatase (a bone formation marker), and tartrate-resistant acid phosphatase 5b (a bone resorption marker) in stored serum samples from 181 hemodialysis patients (age, 68 ± 11 y; 105 males and 76 females; hemodialysis duration, 6.9 ± 5.9 y). The BMD in the distal one-third of the radius and in the ultradistal radius, which are enriched with cortical and cancellous bone, respectively, was examined by dual-energy x-ray absorptiometry.
RESULTS:
Serum sclerostin was 125 ± 53 pmol/L (mean ± SD). Serum sclerostin correlated significantly and negatively with serum bone alkaline phosphatase and tartrate-resistant acid phosphatase 5b (r = -0.265, P < .001; r = -0.218, P < .01, respectively). The BMD in the distal one-third of the radius and in the ultradistal radius both correlated significantly and positively with serum sclerostin levels (r = 0.454, P < .0001; r = 0.329, P < .0001, respectively). In multiple regression analysis, serum sclerostin was associated significantly and independently with BMD of both parts of the radius (β = 0.200, P < .001; β = 0.218, P < .05), after adjustment for age, hemodialysis duration, and bone metabolism markers.
CONCLUSION:
Serum sclerostin was associated significantly, independently, and positively with BMD of both cortical and cancellous bone. Sclerostin is considered to be one of the factors associated with chronic kidney disease-mineral and bone disorder in hemodialysis patients.
AuthorsEiji Ishimura, Senji Okuno, Mitsuru Ichii, Kyoko Norimine, Tomoyuki Yamakawa, Shigeichi Shoji, Yoshiki Nishizawa, Masaaki Inaba
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 99 Issue 11 Pg. 4315-20 (Nov 2014) ISSN: 1945-7197 [Electronic] United States
PMID25093620 (Publication Type: Journal Article)
Chemical References
  • Biomarkers
  • Bone Morphogenetic Proteins
  • Genetic Markers
  • Isoenzymes
  • SOST protein, human
  • tartrate-resistant acid phosphatase
  • Alkaline Phosphatase
  • Acid Phosphatase
Topics
  • Acid Phosphatase (blood)
  • Aged
  • Aged, 80 and over
  • Alkaline Phosphatase (blood)
  • Biomarkers (blood)
  • Bone Density (physiology)
  • Bone Morphogenetic Proteins (blood)
  • Bone Resorption (blood)
  • Bone and Bones (metabolism)
  • Cross-Sectional Studies
  • Female
  • Genetic Markers
  • Humans
  • Isoenzymes (blood)
  • Kidney Failure, Chronic (blood, therapy)
  • Male
  • Middle Aged
  • Renal Dialysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: